What Constitutes a Valid Surrogate End Point in Cancer Clinical Trials?

Yu Shyr; Derek Shyr

doi:10.1001/jamaoncol.2020.1847

What Constitutes a Valid Surrogate End Point in Cancer Clinical Trials?

Yu Shyr
, Derek Shyr

統計與資料科學學系

研究成果: Editorial › 同行評審

9 引文斯高帕斯（Scopus）

原文	English
頁（從 - 到）	1334-1335
頁數	2
期刊	JAMA Oncology
卷	6
發行號	9
DOIs	https://doi.org/10.1001/jamaoncol.2020.1847
出版狀態	Published - 2020 9月

UN SDG

此研究成果有助於以下永續發展目標

SDG 3 良好的健康和福祉

All Science Journal Classification (ASJC) codes

腫瘤科
癌症研究

存取文件

10.1001/jamaoncol.2020.1847

其它文件與鏈接

引用此

@article{115b121f649341c5a0e6e47ba6c503e0,

title = "What Constitutes a Valid Surrogate End Point in Cancer Clinical Trials?",

author = "Yu Shyr and Derek Shyr",

year = "2020",

month = sep,

doi = "10.1001/jamaoncol.2020.1847",

language = "English",

volume = "6",

pages = "1334--1335",

journal = "JAMA Oncology",

issn = "2374-2437",